Two different sizes of Valencia applicators in non-melanoma skin cancer treatment with iridium-192 high-dose-rate brachytherapy

被引:1
作者
Laliscia, Concetta [1 ]
Coccia, Natalina [1 ]
Fuentes, Taiusha [1 ]
Perrone, Franco [2 ]
Paiar, Fabiola [1 ]
机构
[1] Univ Pisa, Dept New Technol & Translat Res, Div Radiat Oncol, Via Roma 67, I-56127 Pisa, Italy
[2] Univ Pisa, Med Phys Dept, Pisa, Italy
关键词
non-melanoma skin cancer; brachytherapy; Valencia applicator; BASAL-CELL CARCINOMA; STANDARDIZED SURFACE APPLICATORS; RADIATION-THERAPY; HDR BRACHYTHERAPY; GUIDELINES; RECURRENCE;
D O I
10.5114/jcb.2021.112111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this retrospective study was to analyze tumor control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) and treated with iridium-192 (192Ir) high-dose-rate (HDR) brachytherapy (BT) using Valencia applicators at the Division of Radiotherapy, University of Pisa. Material and methods: From June 2015 to December 2020, 95 NMSC patients, including 61.5% basal cell carcinoma and 38.5% squamous cell carcinoma patients, with median age of 83 years (range, 32-96 years) were treated. In total, 182 lesions with a diameter <= 25 mm (median, 12 mm) and a depth <= 4 mm, located in scalp (19.2%), face (20.9%), chest (8.8%), nose (16.5%), ear (15.4%), and extremities (19.2%) were analyzed. All lesions were treated with 192Ir-based HDR afterloader using Valencia applicators. 105 lesions (57.7%) were treated with applicator of 20 mm and 77 lesions (42.3%) with applicator of 30 mm in diameter, depending on the size of lesions. Prescribed dose was 40 Gy in 8 fractions (5 Gy/fraction) delivered 2-3 times a week. Biological effective dose (BED) was approximate to 60 Gy. Results: The median follow-up was 14 months (range, 3-59 months). The 2-year local control rate was 96%. According to common terminology criteria for adverse events (CTCAE v. 5.0), G1-G2 acute toxicities included dermatitis (22.0%) and pain (8.2%). The most common G1 late toxicities were hypopigmentation (27.5%) and fibrosis (8.2%), and G2 late toxicity included ulceration (0.5%). No G3 or higher acute or late toxicities were reported. Excellent cosmetic results were observed in 77.5% of the lesions, with one only (0.5%) reported as a poor cosmetic result (ulceration refractory to therapy). Conclusions: HDR-BT using Valencia applicators is a safe, effective, and well-tolerated treatment modality for NMSC, and can be considered a good alternative for treatment, especially in elderly patients who are often unfit for surgery.
引用
收藏
页码:615 / 619
页数:5
相关论文
共 32 条
  • [1] [Anonymous], 2020, CANC FACTS FIGURES 2
  • [2] Melanoma and non-melanoma skin cancer among patients who attended at King Khalid University Hospital in Riyadh, Saudi Arabia from 2007-2018
    Arab, Khalid A.
    AlRuhaili, Amjad
    AlJohany, Tariq
    AlHammad, Reema S.
    [J]. SAUDI MEDICAL JOURNAL, 2020, 41 (07) : 709 - 714
  • [3] Nonmelanoma skin cancer treated with electronic brachytherapy: Results at 1 year
    Bhatnagar, Ajay
    [J]. BRACHYTHERAPY, 2013, 12 (02) : 134 - 140
  • [4] Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
    Chren, Mary-Margaret
    Linos, Eleni
    Torres, Jeanette S.
    Stuart, Sarah E.
    Parvataneni, Rupa
    Boscardin, W. John
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (05) : 1188 - 1196
  • [5] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [6] Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature
    Delishaj, Durim
    Rembielak, Agata
    Manfredi, Bruno
    Ursino, Stefano
    Pasqualetti, Francesco
    Laliscia, Concetta
    Orlandi, Francesca
    Morganti, Riccardo
    Fabrini, Maria Grazia
    Paiar, Fabiola
    [J]. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (06) : 533 - 540
  • [7] Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series
    Delishaj, Durim
    Laliscia, Concetto
    Manfredi, Bruno
    Ursino, Stefano
    Pasqualetti, Francesco
    Lombardo, Ezio
    Perrone, Franco
    Morganti, Riccardo
    Paiar, Fabiola
    Fabrini, Maria Grazia
    [J]. JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (06) : 437 - 444
  • [8] Basal Cell Carcinoma: What's New Under the Sun
    Dessinioti, Clio
    Antoniou, Christina
    Katsambas, Andreas
    Stratigos, Alexander J.
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2010, 86 (03) : 481 - 491
  • [9] The role of radiotherapy in the management of non-melanoma skin cancer
    Garbutcheon-Singh, Kieran B.
    Veness, Michael J.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 (04) : 265 - 272
  • [10] HDR Brachytherapy for Superficial Non-Melanoma Skin Cancers
    Gauden, Ruth
    Pracy, Martin
    Avery, Anne-Marie
    Hodgetts, Ian
    Gauden, Stan
    [J]. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2013, 57 (02) : 212 - 217